Vortioxetine for the Treatment of Major Depression and Neuropsychiatric Co-morbidities After Traumatic Brain Injury (TBI)

Trial Profile

Vortioxetine for the Treatment of Major Depression and Neuropsychiatric Co-morbidities After Traumatic Brain Injury (TBI)

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Vortioxetine (Primary)
  • Indications Depression
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 29 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top